Programmed death-1 & its ligands: promising targets for cancer immunotherapy

Rajeev K Shrimali, John E Janik, Rasha Abu Eid, Mikayel Mkrtichyan, Samir N Khleif

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

Original languageEnglish
Pages (from-to)777-92
Number of pages16
JournalImmunotherapy
Volume7
Issue number7
DOIs
Publication statusPublished - 1 Jul 2015

Fingerprint

Immunotherapy
Ligands
Tumor Escape
Neoplasms
Immune Tolerance
Antibodies
Viral Tumor Antigens
Standard of Care
Melanoma
Therapeutics
T-Lymphocytes
Research
pembrolizumab
ipilimumab
nivolumab

Keywords

  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD274
  • Humans
  • Immunotherapy
  • Melanoma
  • Neoplasm Metastasis
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins B-raf
  • Journal Article
  • Review

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Programmed death-1 & its ligands : promising targets for cancer immunotherapy. / Shrimali, Rajeev K; Janik, John E; Abu Eid, Rasha; Mkrtichyan, Mikayel; Khleif, Samir N.

In: Immunotherapy, Vol. 7, No. 7, 01.07.2015, p. 777-92.

Research output: Contribution to journalArticle

Shrimali, RK, Janik, JE, Abu Eid, R, Mkrtichyan, M & Khleif, SN 2015, 'Programmed death-1 & its ligands: promising targets for cancer immunotherapy' Immunotherapy, vol. 7, no. 7, pp. 777-92. https://doi.org/10.2217/imt.15.49
Shrimali, Rajeev K ; Janik, John E ; Abu Eid, Rasha ; Mkrtichyan, Mikayel ; Khleif, Samir N. / Programmed death-1 & its ligands : promising targets for cancer immunotherapy. In: Immunotherapy. 2015 ; Vol. 7, No. 7. pp. 777-92.
@article{ef11c6645f704374958826c45c6bf4ac,
title = "Programmed death-1 & its ligands: promising targets for cancer immunotherapy",
abstract = "Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.",
keywords = "Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antigens, CD274, Humans, Immunotherapy, Melanoma, Neoplasm Metastasis, Programmed Cell Death 1 Receptor, Proto-Oncogene Proteins B-raf, Journal Article, Review",
author = "Shrimali, {Rajeev K} and Janik, {John E} and {Abu Eid}, Rasha and Mikayel Mkrtichyan and Khleif, {Samir N}",
year = "2015",
month = "7",
day = "1",
doi = "10.2217/imt.15.49",
language = "English",
volume = "7",
pages = "777--92",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Programmed death-1 & its ligands

T2 - promising targets for cancer immunotherapy

AU - Shrimali, Rajeev K

AU - Janik, John E

AU - Abu Eid, Rasha

AU - Mkrtichyan, Mikayel

AU - Khleif, Samir N

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

AB - Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with programmed death-1 (PD-1) and PD-ligand pathway blockade seem promising, making these targets highly sought for cancer immunotherapy. In fact, the anti-PD-1 antibodies, pembrolizumab and nivolumab, were recently approved by the US FDA for the treatment of unresectable and metastatic melanoma resistant to anticytotoxic T-lymphocyte antigen-4 antibody (ipilimumab) and BRAF inhibitor. Here, we discuss strategies of combining PD-1/PD-ligand interaction inhibitors with other immune checkpoint modulators and standard-of-care therapy to break immune tolerance and induce a potent antitumor activity, which is currently a research area of key scientific pursuit.

KW - Animals

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antigens, CD274

KW - Humans

KW - Immunotherapy

KW - Melanoma

KW - Neoplasm Metastasis

KW - Programmed Cell Death 1 Receptor

KW - Proto-Oncogene Proteins B-raf

KW - Journal Article

KW - Review

U2 - 10.2217/imt.15.49

DO - 10.2217/imt.15.49

M3 - Article

VL - 7

SP - 777

EP - 792

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -